<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058717</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY12579</org_study_id>
    <nct_id>NCT04058717</nct_id>
  </id_info>
  <brief_title>Low Nicotine Cigarettes Plus Electronic Cigarettes</brief_title>
  <official_title>Randomized Trial of Low Nicotine Cigarettes Plus Electronic Cigarettes in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the health effects of very low nicotine content in cigarettes,&#xD;
      in conjunction with the availability of nicotine-containing electronic cigarettes (e-cigs)&#xD;
      among smokers with mental health conditions (SMHC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific objective of this study is to recruit a cohort of 240 current exclusive daily&#xD;
      SMHC (diagnosed using the MINI International Neuropsychiatric Interview) and to measure a&#xD;
      comprehensive battery of behavioral and health indicators at 4, 8, 12 and 16 weeks after&#xD;
      being randomized to use either normal nicotine content (NNC) Spectrum cigarettes (11.6 mg&#xD;
      nicotine/cigarette) or very low nicotine content (VLNC) Spectrum cigarettes (0.2 mg&#xD;
      nicotine/cigarette) while also having access to an electronic cigarette (containing either 0&#xD;
      nicotine or high nicotine e-liquid) in a randomized double-blind, placebo-controlled, 2 by 2&#xD;
      design. All participants will be followed up with a study visit 4 weeks after the final&#xD;
      randomized visit to identify whether they have continued to use e-cigs/cigarettes and to&#xD;
      assess their motivation in smoking abstinence.&#xD;
&#xD;
      Our central hypothesis is that key markers of harms to health (e.g. urinary NNAL, exhaled CO,&#xD;
      measures of addiction, and mental distress) will be significantly improved among SMHC who are&#xD;
      provided VLNC cigarettes and high nicotine e-cigs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 X 2 factorial design</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol)</measure>
    <time_frame>Week 16</time_frame>
    <description>Measure of tobacco-specific nitrosamine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled Carbon Monoxide</measure>
    <time_frame>Week 16</time_frame>
    <description>Measure of cigarette smoke exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kessler-6 score</measure>
    <time_frame>Week 16</time_frame>
    <description>Measure of serious psychological distress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn State Cigarette Dependence Index</measure>
    <time_frame>Week 16</time_frame>
    <description>Measure of cigarette dependence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn State Electronic Cigarette Dependence Index</measure>
    <time_frame>Week 16</time_frame>
    <description>Measure of e-cigarette dependence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cigarette abstinence</measure>
    <time_frame>Week 20</time_frame>
    <description>No cigarette use in the past 7 days and exhaled carbon monoxide &lt; 6ppm</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>NNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Nicotine Content research cigarettes</intervention_name>
    <description>Research cigarettes with 11.6 mg nicotine/cigarette.</description>
    <arm_group_label>NNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_label>NNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Nicotine e-cigarette</intervention_name>
    <description>E-cigarette containing high nicotine e-liquid</description>
    <arm_group_label>NNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_label>VLNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Very Low Nicotine Content research cigarettes</intervention_name>
    <description>Research cigarettes with 0.2 mg nicotine/cigarette.</description>
    <arm_group_label>VLNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_label>VLNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Zero Nicotine e-cigarette</intervention_name>
    <description>E-cigarette containing zero nicotine e-liquid</description>
    <arm_group_label>NNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_label>VLNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Smoke &gt;5 cigarettes per day for at least the prior 12 months&#xD;
&#xD;
          -  Smoke regular, filtered cigarettes or machine-rolled cigarettes with a filter&#xD;
&#xD;
          -  Exhaled CO measurement of ≥ 6 parts per million at baseline&#xD;
&#xD;
          -  No serious cigarette smoking quit attempt or use of any FDA-approved smoking cessation&#xD;
             medication in the prior 30 days (includes any nicotine replacement, varenicline,&#xD;
             bupropion [used specifically as a quitting aid])&#xD;
&#xD;
          -  No plans to quit smoking within the next 3 weeks&#xD;
&#xD;
          -  Must be willing to both switch to a different type of cigarette that may contain a&#xD;
             different amount of nicotine and to try an e-cig to substitute for some of their&#xD;
             cigarettes&#xD;
&#xD;
          -  Must be willing and able to respond to contacts from study staff or attend visits over&#xD;
             the study period (not planning to move, not planning extended vacation, no planned&#xD;
             surgeries)&#xD;
&#xD;
          -  9. Must meet lifetime diagnostic criteria for a current or lifetime unipolar or&#xD;
             bipolar mood disorder (e.g. major depressive disorder, major depressive episode, manic&#xD;
             episode, hypomanic episode, bipolar disorder), an anxiety disorder (e.g. panic&#xD;
             disorder, obsessive-compulsive disorder, post-traumatic stress disorder, ,&#xD;
             agoraphobia, social anxiety disorder, generalized anxiety disorder), a psychotic&#xD;
             disorder (e.g. mood disorder or other psychotic disorder), or an eating disorder (e.g.&#xD;
             anorexia or bulimia) based on the MINI-International Neuropsychiatric Interview&#xD;
             Standard (version 7.0.2)&#xD;
&#xD;
          -  Able to read and write in English&#xD;
&#xD;
          -  Able to understand and give informed consent&#xD;
&#xD;
          -  Access to a computer/smartphone with e-mail and a reliable internet connection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant and/or nursing or trying to become pregnant&#xD;
&#xD;
          -  Unstable or significant medical condition in the past 3 months (e.g., recent heart&#xD;
             attack or other serious heart condition, stroke, severe angina, high blood pressure&#xD;
             [systolic &gt;159 mmHg or diastolic &gt;99 mmHg during screening)&#xD;
&#xD;
          -  Respiratory diseases (e.g., exacerbations of asthma or COPD, require oxygen, require&#xD;
             oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe&#xD;
             immune system disorders (e.g., uncontrolled HIV/AIDS, multiple sclerosis symptoms) or&#xD;
             any medical disorder/medication that may affect participant safety or biomarker data&#xD;
&#xD;
          -  Uncontrolled mental illness or substance abuse, or inpatient treatment for these in&#xD;
             the past 6 months&#xD;
&#xD;
          -  Current suicide risk on clinical assessment (above &quot;low risk&quot; score (or ≥ 9) on MINI&#xD;
             diagnostic interview suicide module during screening (34))&#xD;
&#xD;
          -  Use of any non-cigarette nicotine delivery product (e.g., pipe, cigar, dip, chew,&#xD;
             snus, hookah, e-cig, strips or sticks, IQOS) in the past 7 days at screening&#xD;
&#xD;
          -  Use of an e-cig for 5 or more days in the past 28 days or any use in the past 7 days&#xD;
             at screening&#xD;
&#xD;
          -  Use of marijuana or other illegal drugs/prescription drugs for non-medical use&#xD;
             daily/almost daily or weekly in the past 3 months per NIDA Quick Screen&#xD;
&#xD;
          -  Any known allergy to propylene glycol or vegetable glycerin&#xD;
&#xD;
          -  Surgery requiring general anesthesia in the past 6 weeks&#xD;
&#xD;
          -  Unwilling to remain on one flavor of cigarette (regular or menthol) for the duration&#xD;
             of the trial&#xD;
&#xD;
          -  Previous use of SPECTRUM research cigarettes in the past 6 months&#xD;
&#xD;
          -  Other member of household currently participating in the study&#xD;
&#xD;
          -  History of a seizure disorder or had a seizure in the past 12 months&#xD;
&#xD;
          -  Currently taking or have taken medications prescribed to prevent seizures (such as&#xD;
             Carbamazepine or Phenobarbital). Using seizure medications for off-label use&#xD;
             (indications other than treatment for seizures) will not be included as an exclusion,&#xD;
             these will be assessed on a case-by-case basis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Foulds, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolle Krebs, MS</last_name>
    <phone>717-531-5673</phone>
    <email>nkrebs@pennstatehealth.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Foulds, PhD</last_name>
    <phone>717-531-3504</phone>
    <email>jfoulds@psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolle M Krebs, MS</last_name>
      <phone>717-873-2856</phone>
      <email>nkrebs@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Foulds, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Jonathan Foulds</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

